National Conference Presentations on Gynecologic Cancers

Highlights from 2019 SGO Annual Meeting

In March, ovarian cancer researchers, clinicians and advocates gathered to attend the much-anticipated Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer, to discuss the latest cutting edge research.

OCRA Research Advocate, Scientific Advisory Committee member, and ovarian cancer survivor Annie Ellis attended the meeting and wrote a report highlighting the most important and interesting presentations.

Read the full report at: https://ocrahope.org/wp-content/uploads/2019/04/2019-SGO-report-final.pdf

Video Highlights from the OCRA July 2018 National Conference are available at:

https://ocrfa.org/events/conference/2018-presentations/

Dr. Barbara Goff on Ovarian Cancer Update

Dr. Barbara Goff delivered the 14th Annual Susan Patricia Teck Memorial Lecture on October 11 at The George Washington School of Medicine and Health Sciences. Her topic was "Ovarian Cancer: Update on Screening, Early Diagnosis, and Prevention." Dr. Goff, Professor, Gynecologic Oncology Director, Division of Gynecologic Oncology at the University of Washington Medical Center in Seattle, was one of the lead researchers on the groundbreaking 2007 consensus statement that identified four symptoms –bloating, abdominal pain, fullness, and frequent or urgent urination-- that were predictive for ovarian cancer.

The Road Ahead for Ovarian Cancer

Opening the 20th Annual Ovarian Cancer National Conference in Chicago, John Moroney, M.D., underscored the challenges that remain in the early detection and treatment of ovarian cancer, but also the tremendous hope that resides in robust clinical trial research.

Amgen Ovarian Cancer Drug Fails to Improve Overall Survival

Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Patients given the drug, trebananib, along with a chemotherapy agent paclitaxel, experienced overall survival of 19.3 months, compared with 18.3 months for the placebo group. Analysts said oncologists expect the drug to have little or no benefits in terms of overall survival and FDA approval seems unlikely.

Bevacizumab Plus Fosbretabulin Improves Progression-Free Survival in Ovarian Cancer Patients

The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an oral presentation made at the biennial meeting of the International Gynecologic Cancer Society. A study found significant improvement in progression-free survival among patients treated with the combination of bevacizumab and fosbretabulin versus bevacizumab alone, with a median improvement of 2.5 months.